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 None 
 Will discuss off-label uses 
 Traumatic 
 Infectious 
 Genetic 
 Allergic (contact 
dermatitis, drug) 
 Autoimmune 
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PEMPHIGUS GROUP – Cell-Cell Adhesion 
 Pemphigus vulgaris – Desmoglein 1, 3 
 Pemphigus foliaceus – Desmoglein 1 
 Paraneoplastic pemphigus – Desmoglein 3, Plakin family 
members 
 
PEMPHIGOID GROUP – Cell Substrate Adhesion 
 Bullous pemphigoid – BP180, BP240 
 Pemphigoid gestationis – BP180 
Linear IgA Disease – 120 kD processed form of BP180 
 Cicatricial pemphigoid – BP180, Laminin 3,3,2, col VII 
 
MISCELLANEOUS 
  Dermatitis herpetiformis  - e-Transglutaminase 
Epidermolysis bullosa acquisita – Coll VII 
Bullous SLE – Coll VII 
– epidermal   
  
 
 41 year old female 
 August 2007: Developed “bumps” on her 
scalp - diagnosed as psoriasis, then tinea 
 October 2007 – Spread to chest and trunk – 
diagnosed as bullous pemphigoid 
 November 2007 – seen at UIHC, biopsy and 
immunofluorescent studies performed 
 



 Clinical 
 H&E Biopsy 
 Direct Immunofluorescence 
 Indirect Immunofluorescence 
 ELISAs (not for initial screening) 
 70% begin in the mouth.  Scalp is the next 
most common spot.  Left untreated 
widespread involvement will develop. 
 Flaccid blisters that arise on normal 
appearing skin.   
 Significant mucous membrane involvement 

 Average onset 5th decade 
 M=F, more common in Ashkenazi Jewish 
population 
 Generally a life-long disease 
 Pre-steroid era the fatality rate approached 
100% at 5 years 
 Currently: 5-20% at 5 years (mainly due to 
side effects of therapy) 
 
 Autoantibodies 
directed against 
desmosomal 
cadherins – calcium 
dependent cell 
adhesion molecules 
 PV – Desmoglein 3 
 PF – Desmoglein 1 
 Pemphigus foliaceus 
 Paraneoplastic pemphigus 
 Drug induced 
 
 
 
PEMPHIGUS 
FOLIACEUS 
• Blisters at level of the 
stratum corneum 
 
• Flaccid bullae and 
crusts, predominantly in 
sun-exposed areas 
 
• No mucosal involvement 
 
• Tends to respond more 
easily to treatment than 
PV 

 Significant mucous 
membrane 
involvement (often 
ocular 
 Cutaneous 
involvement highly 
variable 
 Non-Hodgkins 
lymphoma, 
Castleman’s tumor 
 PF > PV (4:1) 
 Thiol or sulfur containing drugs: 
penicillamine, captropril, enalapril, 
penicillin, cephalosporins, piroxicam 
 Most resolve when the medication is 
withdrawn 

 A 82 year-old woman is transported from a 
nursing home for a two week history of a 
rash with blisters developing in the past 
week 
 Medical history: diabetic, hypertensive, 
Parkinson’s disease 

BULLOUS PEMPHIGOID 
 M=F, Average age 76 
 IgG and IgE class autoantibodies target 
BP180 (collagen XVII) – a cell-substrate 
adhesion molecule of the hemidesmosome 
 May be associated with other autoimmune 
disorders (thyroid, MS) 
 Risk factors dementia, Parkinson’s disease 
 Average duration: 6 years 
 Pemphigoid gestationis 
 Linear IgA disease 
 Cicatricial pemphigoid 
 Bullous pemphigoid 
like eruption 
 1:10,000 pregnancies 
 Begins in 2-3rd 
trimester, resolves 
post-partum 
 Begins around 
umbilicus in 50% 
 Papules, urticarial 
plaques, vesicles and 
bullae 
 
 “Cluster of Jewels” 
 IgA autoantibodies 
against processed 
form of BP180 
 Drug induced – 
vancomycin – resolves 
with withdrawal of the 
drug 
 Spontaneous 
 Juvenile (CBDC) 
 BP180 (collagen XVII) 
 Laminin 3,3,2 
(epiligrin)** 
 4 subunit of 64 
integrin 
 Collagen VII 
  
 35 patients - 10 cancers 
 14 month +/- onset of blistering 
 Relative risk  7.7 
 Lung, colon, gastric, endometrial 
 
 Acral 
 Non-inflammatory 
 M > F 
 0.5% of diabetic 
patients 
 Heal spontaneously in 
2-6 weeks 
 34 year old man with a 2 month history of 
an extremely pruritic eruption on the 
knees, elbows and sacrum 
 Has been treated for scabies with no 
response 
 Topical steroids do not help 

 Grouped, pruritic vesicles on the 
extensor elbows, knees and sacrum 
 2nd-4th decade, M>F 
 N. European ancestry 
 HLA-A1, HLA-B8, HLA-DR3, HLA-DWQ2 
 
 
IgA 
 90% of DH patients have GSE on biopsy 
 Most are clinically silent 
 15-20% of celiac disease patients will 
develop DH 
 IgA anti-tissue transglutaminase will be 
positive in most DH patients 
 Increased risk of lymphoma (rr 1.7) 
 
 Genetic predisposition to gluten sensitivity 
 IgA antibodies to transglutaminase 
 Antibody-antigen complex deposits in skin 
 IgA antibodies cause PMN chemotaxis and 
attachment 
 PMN release proteolytic enzymes that 
disrupt the BMZ 
 Gluten free diet (months) 
 Dapsone (days) 
 Sulfapyridine 
 Heparin (recalcitrant cases only) 
 
 
 
 
 
Minimal response to steroids 

 EBM lacking 
 Immunosuppressives 
 Prednisone 
 Steroid sparing agents: azathioprine, cytoxan, 
methotrexate, mycophenolate mofetil 
 Other agents: dapsone, minocycline, colchicine 
 Biologics 
 Rituximab 
 Infliximab 
 Misc: plasmapheresis, IVIG 
 
 Baseline/Initiation 
 Consolidation 
 No new lesions 
 Established lesions starting to heal 
 End of consolidation (tapering) 
 No new lesions or pruritus (BP) for 2 weeks 
 Majority (~80%) of established lesions healed 
 Treat! 
 Prednisone 
 Up to 0.75 mg/kg/d (BP) 
 Up to 1.5-2 mg/kg/d (PV) 
 3 weeks 
 Half lives  IgG 7-23 d; IgA 4-5d; IgE 2 d 
 Clobetasol 40 g/d (European) 
 Plasmapheresis 
 Immunoadsorption (not available in US currently) 
 Anti-human IgG 
 Protein A 
 
 
PPD, Ca++, Vit D, bisphosphonates? 
 If cannot get prednisone < 10 mg/d consider 
adjuvant 
 Azathioprine 
 TPMT; low and super-high are problematic 
 2 mg/kg/d 
 Mycophenolate mofetil 
 2-3 gm/d – start low and work up 
 Enteric coated is available 
 Methotrexate 
 Weekly doses similar to psoriatic doses – up to 15 
mg/week if > 60 kg and no major renal dx 
 Cyclophosphamide    
 Love it for DH 
 CP –best if IgA mediated 
 PV – underpowered studies (IgE 
pemphigus, pemphigus herpetiformis?) 
 EBA – works just about as well as 
everything else (ie      ) 
 BP – no data 
 
 
Rule of thumb: IgA or neuts 
 
 Chimeric monoclonal antibody 
 Targets CD-20 positive B lymphocytes – 
removes these cells that are ready to 
transform into autoantibody producing 
short-lived plasma cells 
 Does not bind to stem cells or plasma cells 
 Approved for use in non-Hodgkins 
lymphomas, rheumatoid arthritis 
 Case reports/series of successful treatment 
of PV, PF, PNP, EBA, CP and BP (more than 
100 citations) 
 Dose:  325 mg/m2/week x 4 weeks 
 Alternative:  1000 mg/week x 2, 2 weeks 
apart 
 Variability in how it is given after the 
first cycle – repeat in 6 months vs wait 
for flare 
 Monotherapy? 
Two months after completing 
one cycle of rituximab 

 Serious adverse events – 5-6% (if minimize 
other immunosuppressants) 
 Most commonly infections (sepsis, 
pneumonia) 
 Other reports: prolonged hypo-
gammaglobulinemia, neutropenia, DVT, 
pulmonary embolism 
 Progressive multifocal leukoencephalopathy 
(activation of JC virus – polyoma virus) 

